OREANDA-NEWS. September 13, 2016. BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers,
announced at the 102
nd session of the
American Academy of
Periodontology in
San Diego, Calif., that it has entered into a clinical
research agreement with
The McGuire Institute, a leading practice-based
dental research organization specializing in evidence-based research to
advance the practice of periodontics and dentistry.
The McGuire Institute is led by founder and senior clinical investigator
Michael K. McGuire, D.D.S. and has successfully conducted several
evidence-based, landmark clinical studies on emerging dental materials
and techniques. The Institute has agreed to conduct an independent,
multi-center research study focused on BIOLASE laser technology.
The initial project between BIOLASE and The McGuire Institute will
include rigorous, multi-center, blinded research using BIOLASE laser
solutions for the management of periodontal disease. McGuire will also
incorporate the institution’s groundbreaking work on patient-reported
outcomes and patient-driven research, resulting in statistically
meaningful evidence to further help patients and practitioners evaluate
the benefits of laser therapy versus traditional techniques.
“We are very excited about the potential of our agreement with BIOLASE
to yield high-level evidence regarding the use of lasers in the
management of periodontal disease,” said Dr. McGuire. “We look forward
to continuing to raise the bar in the quality and impact of clinical
research conducted for the benefit of our patients and practitioners.”
BIOLASE has made rigorous evidence-based clinical research a priority in
its efforts to demonstrate the benefits of laser dentistry for patients
and clinicians.
“The opportunity to conduct independent clinical research with a highly
esteemed group like The McGuire Institute is an important step forward
for the company’s clinical research efforts,” said
Harold C. Flynn, Jr.,
President and CEO of BIOLASE. “Their network of highly trained
clinicians, who are also practicing periodontists and oral surgeons,
will be instrumental in bolstering the objective evidence necessary to
significantly expand adoption of lasers in dentistry.”
The prevalence of periodontal disease in the U.S. is an epidemic that
research has indicated may lead to complications such as heart disease,
diabetes and complications with pregnancy. According to the American
Dental Association, 69.7% of adults in the United States over the age of
30 have some form of periodontal disease. Of those affected,
approximately 50% of them may require surgical intervention by a dental
professional, which may potentially be performed less invasively with
similar or improved outcomes than with traditional techniques.
About BIOLASE, Inc.
BIOLASE, Inc. is a medical device company that develops, manufactures,
markets, and sells laser systems in dentistry and medicine and also
markets, sells, and distributes dental imaging equipment, including
digital x-rays and CAD/CAM scanners. BIOLASE’s products are focused on
technologies that advance the practice of dentistry to both the dentist
and their patients. The Company's proprietary laser products incorporate
approximately 255 patented and 90 patent-pending technologies designed
to provide biologically clinically superior performance with less pain
and faster recovery times. Its innovative products provide cutting-edge
technology at competitive prices to deliver the best results for
dentists and patients. BIOLASE's principal products
are revolutionary dental laser systems that perform a broad range of
dental procedures, including cosmetic and complex surgical applications,
and a full line of dental imaging equipment. BIOLASE has sold more than
32,000 laser systems to date in over 90 countries around the world.
Laser products under development address the Company’s core dental
market and other adjacent medical and consumer markets.
For updates and information on WaterLase® iPlus™ and laser dentistry,
find BIOLASE online at www.biolase.com,
Facebook at www.facebook.com/biolase,
Twitter at www.twitter.com/biolaseinc,
LinkedIn at www.linkedin.com/company/biolase,
and YouTube at www.youtube.com/biolasevideos.
BIOLASE® and WaterLase® are registered trademarks of BIOLASE,
Inc.
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995
Statements contained in this press release that refer
to BIOLASE's estimated or anticipated future results or other
non-historical facts are forward-looking statements, as are any
statements in this press release concerning prospects related
to BIOLASE's strategic initiatives and anticipated financial
performance. Forward-looking statements can also be identified through
the use of words such as “anticipates,” “expects,” “intends,” “plans,”
“believes,” “seeks,” “estimates,” “may,” “will,” and variations of these
words or similar expressions. Readers are cautioned not to place undue
reliance on these forward-looking statements, which
reflect BIOLASE's current expectations regarding existing trends, our
strategic initiatives, the closing of the private placement and expected
use of proceeds and speak only as of the date of this release. Actual
results may differ materially from BIOLASE’s current expectations
depending upon a number of factors affecting BIOLASE’s business. These
factors include, among others, adverse changes in general economic and
market conditions, competitive factors including but not limited to
pricing pressures and new product introductions, uncertainty of customer
acceptance of new product offerings and market changes, risks associated
with managing the growth of the business, and those other risks and
uncertainties that may be detailed, from time-to-time,
in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any
responsibility to revise or update any forward-looking statements
contained herein.
Комментарии